- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00144027
Patient-Centered Medication Adherence Intervention for Schizophrenia (AMAIS)
6. april 2015 opdateret af: US Department of Veterans Affairs
Efficacious antipsychotic medication treatments for schizophrenia are available; however , antipsychotic regimens frequently do not achieve their potential because of poor medication adherence.
To date, medication adherence interventions have not been widely adopted or sustained in "real-world" practice settings.
One reason for this is the substantial resource investment necessary to implement and sustain available interventions.
In response to these problems, we developed a patient-centered adherence intervention based on patient-identified barriers, facilitators, and motivators (BFMs) for medication adherence.
The intervention includes a BFM survey (checklist and preference weighting exercise to determine the patient's most important BFM) and a brief list of adherence enhancing suggestions (Options List) tailored to the patient-identified BFMs and compatible with CPRS.
The long-term objective of this proposed research is to improve antipsychotic medication adherence and clinical outcomes for patients with schizophrenia using a cost-effective medication adherence intervention.
The short-term objectives are to refine and test a patient-centered medication adherence intervention for VA patients with schizophrenia and specifically to: 1. Enhance the feasibility and acceptability of the BFM intervention by reducing the burden on patients and mental health providers through BFM checklist item reduction, provider intervention input, and patient intervention input.
We hypothesize that our use of end-user input will result in at least 80% of intervention patients having documentation of a BFM intervention in CPRS. 2. Compare the effects of the BFM intervention versus usual care on changes in medication adherence and schizophrenia symptom severity.
We hypothesize that the intervention will result in a) greater medication adherence and b) lower schizophrenia symptom severity than usual care.
3. Exploratory objective: compare the effects of the BFM intervention versus usual care on changes in patient health-related quality of life.
We hypothesize that the intervention will result in greater health-related quality of life than usual care.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
BFM intervention refinement will be accomplished in five phases.
Phase one will include reducing the number of items in the BFM checklist by administering the expanded checklist to at least 50 patients with schizophrenia and using the standard psychometric item-reduction strategies to create a shorter checklist.
In phase two we will conduct mental health provider focus groups to discuss the content of the Options List and the delivery of the intervention.
In phase three we will automate the BFM intervention using an existing web-based computer touch-screen platform.
In phase four we will conduct individual patient debriefing interviews with 30 patients to evaluate the understandability of the BFM survey.
In phase five we will evaluate the test/re-test reliability of the survey in a new sample of 30 patients.
BFM intervention implementation will include a stratified randomization of patients to the BFM intervention or usual care.
BFM intervention evaluation will include testing the feasibility, acceptability, and outcomes associated with the intervention versus usual care in a single trial with 200 patients (100 intervention and 100 usual care).
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
75
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Arkansas
-
No. Little Rock, Arkansas, Forenede Stater, 72114-1706
- Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 70 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- medical chart diagnosis of schizophrenia or schizoaffective disorder;
- currently prescribed outpatient antipsychotic medication (oral or depot);
- patient must have adequate capacity to provide informed consent, understand the nature of the study, and sign an informed consent document.
Exclusion Criteria:
- significant cognitive impairment as indicated by a score > 10 on the Blessed Orientation-Memory-Concentration (BOMC) Test.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Ingen indgriben: Control
The control group will receive treatment as usual; meaning patients in the control group will not receive the medication adherence intervention.
|
|
|
Eksperimentel: Antipsychotic adherence intervention
Antipsychotic Medication Adherence Intervention which included the Barriers, Facilitators, and Motivators Checklist summary and Adherence tips provided in hard copy to patient and electronic copy to mental health provider.
|
The medication adherence intervention will include using a computer to complete a brief set of questions related to medication adherence before mental health clinic visits.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Antipsychotic Medication Adherence
Tidsramme: 6-months
|
The self-report adherence measure asked patients to think about the past four weeks and report to what extent they took their medication for mental, emotional, or nervous problems and report the result on a 5-point Likert scale ranging from 'I never missed taking my medicine' to 'I stopped taking the medicine altogether'.
Patients who received depot injections were asked to think about the past six months.
Self-report adherence was defined as 1=I never missed taking my medicine' and 0=any other response to the medication adherence question.
|
6-months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Jeffrey M. Pyne, MD, Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. december 2004
Primær færdiggørelse (Faktiske)
1. juni 2009
Studieafslutning (Faktiske)
1. juli 2009
Datoer for studieregistrering
Først indsendt
1. september 2005
Først indsendt, der opfyldte QC-kriterier
1. september 2005
Først opslået (Skøn)
2. september 2005
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
24. april 2015
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
6. april 2015
Sidst verificeret
1. juli 2014
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IIR 03-257
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .